socalTECH

OCTOBER 1, 2013

Thousand Oaks-based Amgen reported this morning that it has completed its tender offer for Onyx Pharmaceuticals , and now expects its acquisition to complete today. billion net of estimated cash at Onyx. Amgen said the deal is worth $9.7

Thousand Oaks 173

Thousand Oaks .Net Acquisition Report 173

socalTECH

AUGUST 26, 2013

Thousand Oaks-based biotech giant Amgen announced Sunday that it has acquired San Francisco biopharmaceuticals company Onyx Pharmaceuticals , in a deal worth $10.4 Onyx is a developer of biopharmaceuticals used to help patients with cancer. billion net of the estimated cash on hand at Onyx. The deal is worth $9.7

Thousand Oaks 153

Thousand Oaks .Net Acquisition Help 153

socalTECH

JANUARY 27, 2011

In a sign that Thousand Oaks-based Nexsan might be ramping up its IPO efforts again, after a delay last year, the firm filed an updated S-1 this week. The provider of data storage equipment reported that it had net income of $0.5M in net income of $19.28M in revenues for the three months ended September 30, 2010.

Thousand Oaks 147

Thousand Oaks .Net Report Marketing 147

socalTECH

MAY 23, 2011

Thousand Oaks-based Ceres , the developer of seeds aimed at producing renewable, biomass feedstocks for the biofuels industry, has filed for an IPO. The firm said it had a net loss of $22.5M The firm's IPO is being underwritten by Goldman, Sachs & co., and Barclays Capital. and Barclays Capital. on revenues of $6.6M

Thousand Oaks 140

Thousand Oaks .Net Capital Marketing 140

socalTECH

JUNE 17, 2010

a developer of high speed, analog semiconductors, has filed for an IPO, saying late Wednesday evening in a filing with the SEC it is looking to raise up to $115M in an IPO on the NYSE. In its S-1, the firm said it had net income of $7.3M In the latest Southern California firm to target the public markets, Inphi Corp. , READ MORE>>.

Westlake Village 133

Westlake Village Thousand Oaks Southern California .Net 133

Xconomy

AUGUST 26, 2016

—Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, said that the FDA rejected its drug etelcalcetide (Parasbiv) , a treatment for patients with an excess of damaging hormone release because of chronic kidney disease. Morgan party. The firm has since pledged to help close the gender gap among biotech leadership.

Pricing 40

Pricing Thousand Oaks Startup Research 40